Tag: dual anti-platelet therapy (DAPT)
1. Guided selection of antiplatelet therapy reduced rates of major adverse cardiovascular event rates compared to standard therapy.
2. Guided selection strategy was beneficial for both escalation and de-escalation of standard therapy, balancing patient-dependent ischemic and bleeding risks.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Patients who undergo percutaneous coronary intervention (PCI)...
1. There was no significant difference in periprocedural myonecrosis between ticagrelor and clopidogrel among patients undergoing high-risk elective PCI.
2. Ticagrelor treatment was associated with an increased rate of minor bleeding at 30 days post-operation.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Percutaneous coronary intervention (PCI) provides a safe therapeutic option for...
1. After successful transcatheter aortic valve replacement, compared to an anti-platelet based strategy, patients that received an anti-coagulation strategy including rivaroxaban at a dose of 10 mg daily had a higher risk of death, thromboembolic complications, and bleeding.
Evidence Rating: 1 (Excellent)
Transcatheter aortic-valve replacement (TAVR) is a treatment option for patients...
1. In this pre-specified ancillary study of a randomized control trial, ticagrelor alone after one month was found non-inferior, but not superior, to dual antiplatelet therapy in preventing ischemic events after drug eluting coronary stenting.
2. Ticagrelor did not decrease bleeding risk compared with dual antiplatelet therapy.
Evidence Rating Level: 2...
The current standard therapy following percutaneous coronary intervention (PCI) with drug-eluting stents (DES) is dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor, followed by aspirin (ASA) monotherapy. P2Y12 inhibitor monotherapy has recently been suggested as an alternative to DAPT, with studies showing reduced risk of subsequent ischemic...
1. A monoclonal antibody fragment to ticagrelor, PB2452, increased platelet function significantly in healthy patients given the oral P2Y12 inhibitor ticagrelor.
2. Adverse effects were mainly limited to the infusion site, with limited systemic events.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Antiplatelet therapy is used extensively for prevention of cardiovascular occlusive events. Many...
1. A monoclonal antibody fragment to ticagrelor, PB2452, increased platelet function significantly in healthy patients given the oral P2Y12 inhibitor ticagrelor.
2. Adverse effects were mainly limited to the infusion site, with limited systemic events.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Antiplatelet therapy is used extensively for prevention of cardiovascular occlusive...